Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Go back to Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)| Merck & Co. (NYSE: MRK) | Delayed: 115.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.48 | 52 Week High | $65.46 | |||
| Open | $115.48 | 52 Week Low | $47.97 | |||
| Day High | $115.48 | P/E | 78.56 | |||
| Day Low | $115.48 | EPS | $1.47 | |||
| Volume | 4,822 | |||||
